KRAS Mutation Analysis Helps to Differentiate Between Pulmonary Metastasis from Colon Adenocarcinoma In Situ and Primary Lung Adenocarcinoma  by Ortiz, Taylor M. et al.
CASE REPORT
KRAS Mutation Analysis Helps to Differentiate Between
Pulmonary Metastasis from Colon Adenocarcinoma In Situ
and Primary Lung Adenocarcinoma
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and Daniel B. Costa, MD, PhD†
A 69-year-old woman never-smoker was noted to have asolitary 4-cm lesion in the left upper lobe on routine
preoperative chest x-ray before elective hip replacement.
Chest computed tomography redemonstrated the spiculated
4  3.3-cm lesion. Positron emission tomography-computed
tomography confirmed that the lesion was fluorodeoxyglu-
cose-avid with no other sites of fluorodeoxyglucose avidity
(Figure 1). The patient underwent a core needle biopsy of the
lung lesion showing a cytokeratin (CK) 20 and caudal type
homeobox transcription factor 2–positive adenocarcinoma,
which was negative for CK7 and thyroid transcription fac-
tor-1. The expected immunohistochemical markers for a
primary lung adenocarcinoma are CK7 and thyroid transcrip-
tion factor-1, whereas the usual markers for a primary colo-
rectal adenocarcinoma are CK20 and caudal type homeobox
transcription factor 2. The patient underwent a video-assisted
thoracoscopic lobectomy and mediastinal lymphadenectomy
revealing a 3.8-cm adenocarcinoma with the same histologic
(Figure 2A) and immunophenotype (Figure 3) as the previous
biopsy. One inferior mediastinal lymph node (level 9L) was
also involved with tumor, and levels 5, 10L, 11L, and 12L
nodes were negative for disease. A colonoscopy, upper en-
doscopy, and capsule video enteroscopy did not show any
evidence of a primary tumor. Seven years before the discov-
ery of the lung mass, she had a 2-cm sigmoid adenoma with
areas of high-grade dysplasia (Figure 2B) and carcinoma in
situ resected endoscopically in a piecemeal fashion.
Her resected lung tumor was sent for genetic testing
and found to harbor a Kirsten ras sarcoma viral oncogene
homolog (KRAS) gene codon 12 GGT to GTT (glycine to
valine) missense mutation (KRAS G12V). The tumor was
wild-type for the epidermal growth factor receptor gene.
Given there was no evidence of primary colorectal tumor
on endoscopy, the archived, paraffin-embedded sigmoid
adenoma was also genotyped and found to carry the same
KRAS codon 12 GTT transversion. This suggested that the
lung tumor was a late recurrence from the original KRAS
mutant sigmoid carcinoma in situ. She was subsequently
found to have multiple new pulmonary lesions.
DISCUSSION
Molecular signatures are being more commonly used to
help to determine the primary site of carcinomas of unknown
primary tumors and differentiate metastatic from primary
tumors.1
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FIGURE 1. A, Computed tomography of the lung. B,
Positron emission tomography.
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In this case, clinically available KRAS mutation testing
demonstrated identical genetic alterations in both a lung mass
and a sigmoid adenoma. The majority of KRAS mutations in
colorectal tumors occur in codon 12, with GGT to GTT
transversions (G12V), as seen in this case, present in 6.7% of
2721 patients in one compilation study.2 The size of colorec-
tal polyps is related to the presence of KRAS mutations, and
polyps greater than 1 cm have RAS mutations at a rate of
58%.3 KRAS mutations in never-smokers with non-small cell
lung cancers are more often transitions (G to A) than trans-
versions (G to C or G to T), and the opposite is true for
smoking-related non-small cell lung cancers.4
This patient’s sigmoid polyp possessed features that
correlate with a higher rate of advanced colon cancer: larger
than 1 cm in size and high-grade dysplasia or carcinoma in
situ.5 In patients with endoscopic resection of adenomatous
polyps, endoscopic resection reduces the rate of development
of colorectal cancer from 2.5 to 5.8 per 1000 person-years to
0.6 per 1000 person-years.5 However, late metastasis to the
lung can occur.
Although one cannot definitively know that this pa-
tient’s lung lesion arose from the sigmoid polyp, the histo-
logic characteristics, the lack of identifiable primary tumor on
multiple endoscopies, and the identical KRAS transversion in
both masses make this the most likely case. Tumor genotype
will continue to enhance our ability to diagnose and treat
malignant tumors.
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FIGURE 2. A, Lung with left upper
lobe adenocarcinoma (hematoxylin
and eosin). B, Sigmoid polyp with
high-grade dysplasia (hematoxylin
and eosin).
FIGURE 3. Immunohistochemical
profile of the resected tumor. A,
CK7; (B) CK20; (C) TTF-1; (D)
CDX-2. CK, cytokeratin; TTF-1, thy-
roid transcription factor-1; CDX-2,
caudal type homeobox transcription
factor 2.
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